Founded by internationally renowned experts in E3 ubiquitin ligase regulation and structure, Nurix has evolved into a powerhouse of targeted protein degradation. Our team includes industry-leading scientific innovators who have built a formidable advantage in the science of protein degradation, coupled with seasoned executives who possess demonstrated expertise in scaling biotech companies.
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D., has served as Chief Executive Officer and a member of the company’s board of directors since September 2014. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer, and as a member of the board of directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D., has served as Chief Executive Officer and a member of the company’s board of directors since September 2014. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer, and as a member of the board of directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Hans van Houte
Chief Financial Officer
Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company’s finance team since 2015. Mr. van Houte began his biotechnology finance career as Controller, Treasurer, and Principal Accounting Officer at Vertex Pharmaceuticals, where he helped build the financial and accounting organization post-IPO to support growth from a $100 million to a multibillion market capitalization. Mr. van Houte previously held senior financial roles in biotechnology companies including Vice President, Finance and Operations at Trubion Pharmaceuticals, Inc., where he was part of the team that took Trubion public in October 2006. Prior to joining Nurix, Mr. van Houte was a managing partner at Bionation LLC, a financial consulting firm, and served as acting CFO for multiple new biotechnology companies formed with investments totaling over $150 million from Third Rock Ventures and The Column Group. Mr. van Houte holds a B.S. in Business Administration, Finance and Accounting from Babson College.
Hans van Houte
Chief Financial Officer
Hans van Houte
Chief Financial Officer
Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company’s finance team since 2015. Mr. van Houte began his biotechnology finance career as Controller, Treasurer, and Principal Accounting Officer at Vertex Pharmaceuticals, where he helped build the financial and accounting organization post-IPO to support growth from a $100 million to a multibillion market capitalization. Mr. van Houte previously held senior financial roles in biotechnology companies including Vice President, Finance and Operations at Trubion Pharmaceuticals, Inc., where he was part of the team that took Trubion public in October 2006. Prior to joining Nurix, Mr. van Houte was a managing partner at Bionation LLC, a financial consulting firm, and served as acting CFO for multiple new biotechnology companies formed with investments totaling over $150 million from Third Rock Ventures and The Column Group. Mr. van Houte holds a B.S. in Business Administration, Finance and Accounting from Babson College.
Hans van Houte
Chief Financial Officer
Gwenn M. Hansen, Ph.D.
Chief Scientific Officer
Gwenn M. Hansen, Ph.D., has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Dr. Hansen has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery and leading the company’s discovery organization. Prior to joining Nurix, Dr. Hansen was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.
Gwenn M. Hansen, Ph.D.
Chief Scientific Officer
Gwenn M. Hansen, Ph.D.
Chief Scientific Officer
Gwenn M. Hansen, Ph.D., has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Dr. Hansen has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery and leading the company’s discovery organization. Prior to joining Nurix, Dr. Hansen was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.
Gwenn M. Hansen, Ph.D.
Chief Scientific Officer
Christine Ring, Ph.D., J.D.
Chief Legal Officer and Chief Compliance Officer
Christine Ring, Ph.D., J.D., has served as Chief Legal Officer and Chief Compliance Officer of Nurix since October 2023, and has served as the company’s Secretary since March 2020 and General Counsel since September 2019. Prior to joining Nurix, Dr. Ring held multiple positions assisting companies protect intellectual property, engage in licensing transactions, raise capital, and transition from private companies into public companies. Her most recent corporate positions were as Senior Vice President, Legal at Dermira, Inc., a biotechnology company focused on medical dermatology, and as Senior Vice President of Technology, Strategy & Licensing at Amyris, Inc., a biotechnology company focused on renewable fuels and specialty chemicals. Dr. Ring has served on the board of directors of BIOMILQ, Inc. since February 2022, and has served as board chair since March 2023. Dr. Ring holds an A.B. in Biophysics from the University of California, Berkeley, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and a J.D. from the University of California, Hastings College of the Law.
Christine Ring, Ph.D., J.D.
Chief Legal Officer and Chief Compliance Officer
Christine Ring, Ph.D., J.D.
Chief Legal Officer and Chief Compliance Officer
Christine Ring, Ph.D., J.D., has served as Chief Legal Officer and Chief Compliance Officer of Nurix since October 2023, and has served as the company’s Secretary since March 2020 and General Counsel since September 2019. Prior to joining Nurix, Dr. Ring held multiple positions assisting companies protect intellectual property, engage in licensing transactions, raise capital, and transition from private companies into public companies. Her most recent corporate positions were as Senior Vice President, Legal at Dermira, Inc., a biotechnology company focused on medical dermatology, and as Senior Vice President of Technology, Strategy & Licensing at Amyris, Inc., a biotechnology company focused on renewable fuels and specialty chemicals. Dr. Ring has served on the board of directors of BIOMILQ, Inc. since February 2022, and has served as board chair since March 2023. Dr. Ring holds an A.B. in Biophysics from the University of California, Berkeley, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and a J.D. from the University of California, Hastings College of the Law.
Christine Ring, Ph.D., J.D.
Chief Legal Officer and Chief Compliance Officer
Jason Kantor, Ph.D.
Chief Business Officer
Jason Kantor, Ph.D., has served as Chief Business Officer of Nurix since October 2023, and served in senior finance and business strategy roles since joining the company in July 2020. Prior to joining Nurix, Dr. Kantor served as a Senior Biopharma Analyst at Artisan Partners, where he covered industry trends for both large and small cap biotech and pharma companies globally. He also served as Board President at Biotech Partners, meeting the non-profit’s goals of increasing corporate sponsorship and gaining support from local government. Dr. Kantor previously served as Managing Director, Biotechnology Analyst at Credit Suisse, RBC Capital Markets and WR Hambrecht + Co, focusing on innovative biotech companies and building successful healthcare and research franchises. Prior to that, he held a position as Vice President, Biotechnology Analyst at JP Morgan Chase & Co. Dr. Kantor holds a B.A. in Biology from the University of California, San Diego and a Ph.D. in Cell and Development Biology from Harvard University.
Jason Kantor, Ph.D.
Chief Business Officer
Jason Kantor, Ph.D.
Chief Business Officer
Jason Kantor, Ph.D., has served as Chief Business Officer of Nurix since October 2023, and served in senior finance and business strategy roles since joining the company in July 2020. Prior to joining Nurix, Dr. Kantor served as a Senior Biopharma Analyst at Artisan Partners, where he covered industry trends for both large and small cap biotech and pharma companies globally. He also served as Board President at Biotech Partners, meeting the non-profit’s goals of increasing corporate sponsorship and gaining support from local government. Dr. Kantor previously served as Managing Director, Biotechnology Analyst at Credit Suisse, RBC Capital Markets and WR Hambrecht + Co, focusing on innovative biotech companies and building successful healthcare and research franchises. Prior to that, he held a position as Vice President, Biotechnology Analyst at JP Morgan Chase & Co. Dr. Kantor holds a B.A. in Biology from the University of California, San Diego and a Ph.D. in Cell and Development Biology from Harvard University.
Jason Kantor, Ph.D.
Chief Business Officer
Pasit Phiasivongsa, Ph.D.
Chief Technical Officer
Pasit Phiasivongsa, Ph.D., has served as Chief Technical Officer of Nurix since May 2024. Dr. Phiasivongsa served as Nurix’s Executive Vice President, Technical Operations from October 2023 through April 2024, and as the company’s Senior Vice President, Technical Operations from August 2022 through September 2023. Prior to joining Nurix, Dr. Phiasivongsa served as Senior Vice President, Pharmaceutical Development & Manufacturing at Kronos Bio, where he led all CMC development, manufacturing, and supply chain-related activities. Before Kronos, Dr. Phiasivongsa served as Senior Vice President, Technical Operations at Principia Biopharma, where he incorporated key innovations into CMC development and manufacturing. Prior to Principia, he was Vice President, Pharmaceutical Development at Tobira Therapeutics, where he was responsible for CMC-related activities and led the intellectual property strategy and development for the company’s core assets. Early in his career, he held positions in drug discovery, development, and manufacturing. He is listed on 28 U.S.-issued patents and more than 30 patent applications. Dr. Phiasivongsa earned his B.S. in Biochemistry and Ph.D. in Pharmaceutical and Chemical Sciences from the University of the Pacific, Stockton.
Pasit Phiasivongsa, Ph.D.
Chief Technical Officer
Pasit Phiasivongsa, Ph.D.
Chief Technical Officer
Pasit Phiasivongsa, Ph.D., has served as Chief Technical Officer of Nurix since May 2024. Dr. Phiasivongsa served as Nurix’s Executive Vice President, Technical Operations from October 2023 through April 2024, and as the company’s Senior Vice President, Technical Operations from August 2022 through September 2023. Prior to joining Nurix, Dr. Phiasivongsa served as Senior Vice President, Pharmaceutical Development & Manufacturing at Kronos Bio, where he led all CMC development, manufacturing, and supply chain-related activities. Before Kronos, Dr. Phiasivongsa served as Senior Vice President, Technical Operations at Principia Biopharma, where he incorporated key innovations into CMC development and manufacturing. Prior to Principia, he was Vice President, Pharmaceutical Development at Tobira Therapeutics, where he was responsible for CMC-related activities and led the intellectual property strategy and development for the company’s core assets. Early in his career, he held positions in drug discovery, development, and manufacturing. He is listed on 28 U.S.-issued patents and more than 30 patent applications. Dr. Phiasivongsa earned his B.S. in Biochemistry and Ph.D. in Pharmaceutical and Chemical Sciences from the University of the Pacific, Stockton.
Pasit Phiasivongsa, Ph.D.
Chief Technical Officer
Paula O’Connor, M.D.
Chief Medical Officer
Paula O’Connor, M.D., has served as Chief Medical Officer of Nurix since May 2024. Dr. O’Connor served as Executive Vice President and Head of Clinical Development from February 2024 through April 2024, and as the company’s Senior Vice President of Clinical Development from September 2022 through January 2024. Dr. O’Connor is trained as a hematologist-oncologist with more than 20 years of drug development expertise. Prior to joining Nurix, Dr. O’Connor held senior level positions in Clinical Development and Medical Affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech. Dr. O’Connor completed her fellowships in Hematology, Oncology, and AIDS Oncology at the combined programs of the Massachusetts General, Brigham and Women’s, and Dana Farber Cancer Institute. She holds a B.A. in Psychology-Biology from Yale University and an M.D. from Stanford University.
Paula O’Connor, M.D.
Chief Medical Officer
Paula O’Connor, M.D.
Chief Medical Officer
Paula O’Connor, M.D., has served as Chief Medical Officer of Nurix since May 2024. Dr. O’Connor served as Executive Vice President and Head of Clinical Development from February 2024 through April 2024, and as the company’s Senior Vice President of Clinical Development from September 2022 through January 2024. Dr. O’Connor is trained as a hematologist-oncologist with more than 20 years of drug development expertise. Prior to joining Nurix, Dr. O’Connor held senior level positions in Clinical Development and Medical Affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech. Dr. O’Connor completed her fellowships in Hematology, Oncology, and AIDS Oncology at the combined programs of the Massachusetts General, Brigham and Women’s, and Dana Farber Cancer Institute. She holds a B.A. in Psychology-Biology from Yale University and an M.D. from Stanford University.
Paula O’Connor, M.D.
Chief Medical Officer
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D., has served as Chief Executive Officer and a member of the company’s board of directors since September 2014. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer, and as a member of the board of directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Arthur T. Sands, M.D., Ph.D., has served as Chief Executive Officer and a member of the company’s board of directors since September 2014. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer, and as a member of the board of directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.
Arthur T. Sands, M.D., Ph.D.
President, Chief Executive Officer, and Board Director
Julia P. Gregory
Chair
Julia P. Gregory has served as Chair of our board of directors since May 2024 and as a member of our board of directors since August 2019. Ms. Gregory is currently Chair and Chief Executive Officer of Isometry Advisors, Inc., a biotechnology financial, strategy, and management advisory firm. Ms. Gregory formerly served as Chief Executive Officer at ContraFect Corporation, a biotechnology company focused on therapeutics for drug resistant infectious diseases, from November 2013 through March 2016, and as a member of its board of directors from April 2014 through March 2016. Prior to her appointment as Chief Executive Officer, Ms. Gregory served as ContraFect’s Executive Vice President and Chief Financial Officer from July 2012 to November 2013. From 2009 to August 2011, Ms. Gregory served as President and Chief Executive Officer of Five Prime Therapeutics, Inc., and from 2000 to 2008 she served as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. In addition, Ms. Gregory has twenty years of investment banking experience, including at Dillon, Read & Co. and at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory currently serves on the board of directors of Biohaven Ltd. and Spinal Simplicity, LLC. Ms. Gregory holds a B.A. from George Washington University and an M.B.A. from the Wharton School at the University of Pennsylvania.
Julia P. Gregory
Chair
Julia P. Gregory
Chair
Julia P. Gregory has served as Chair of our board of directors since May 2024 and as a member of our board of directors since August 2019. Ms. Gregory is currently Chair and Chief Executive Officer of Isometry Advisors, Inc., a biotechnology financial, strategy, and management advisory firm. Ms. Gregory formerly served as Chief Executive Officer at ContraFect Corporation, a biotechnology company focused on therapeutics for drug resistant infectious diseases, from November 2013 through March 2016, and as a member of its board of directors from April 2014 through March 2016. Prior to her appointment as Chief Executive Officer, Ms. Gregory served as ContraFect’s Executive Vice President and Chief Financial Officer from July 2012 to November 2013. From 2009 to August 2011, Ms. Gregory served as President and Chief Executive Officer of Five Prime Therapeutics, Inc., and from 2000 to 2008 she served as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. In addition, Ms. Gregory has twenty years of investment banking experience, including at Dillon, Read & Co. and at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory currently serves on the board of directors of Biohaven Ltd. and Spinal Simplicity, LLC. Ms. Gregory holds a B.A. from George Washington University and an M.B.A. from the Wharton School at the University of Pennsylvania.
Julia P. Gregory
Chair
Anil Kapur
Board Director
Anil Kapur has served as a member of our board of directors since October 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets, with key achievements that include the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. From December 2019 through August 2024, Mr. Kapur served as Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation, a commercial-stage biopharmaceutical company. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019, and Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb, from October 2016 until February 2018. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, from 2015 through its acquisition by Shire plc in 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at Janssen Pharmaceuticals, a Johnson & Johnson company. As Vice President, Commercial Leader, Hematology Franchise in Janssen’s Global Commercial Strategy Organization, Mr. Kapur led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets. Mr. Kapur currently serves on the board of directors of Verastem, Inc. Mr. Kapur holds a BE in Mechanical Engineering from Birla Institute of Technology in India, an MS in Industrial Engineering from Louisiana Tech University, and an MBA from the Fuqua School of Business at Duke University.
Anil Kapur
Board Director
Anil Kapur
Board Director
Anil Kapur has served as a member of our board of directors since October 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets, with key achievements that include the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. From December 2019 through August 2024, Mr. Kapur served as Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation, a commercial-stage biopharmaceutical company. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019, and Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb, from October 2016 until February 2018. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, from 2015 through its acquisition by Shire plc in 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at Janssen Pharmaceuticals, a Johnson & Johnson company. As Vice President, Commercial Leader, Hematology Franchise in Janssen’s Global Commercial Strategy Organization, Mr. Kapur led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets. Mr. Kapur currently serves on the board of directors of Verastem, Inc. Mr. Kapur holds a BE in Mechanical Engineering from Birla Institute of Technology in India, an MS in Industrial Engineering from Louisiana Tech University, and an MBA from the Fuqua School of Business at Duke University.
Anil Kapur
Board Director
Lori A. Kunkel, M.D.
Board Director
Lori A. Kunkel, M.D., has served as a member of our board of directors since July 2019. Dr. Kunkel is a biotechnology consultant at LAK505, LLC (previously D2D, LLC), where she advises on drug development, strategy and commercialization, a position she has held since 2004. Dr. Kunkel currently serves on the board of directors of Enliven Therapeutics, Inc., Oric Pharmaceuticals, Inc. and K36 Therapeutics, Inc. She previously served as a director of Loxo Oncology, Inc. from October 2014 until February 2019, Tocagen from September 2015 to June 2020, Maverick Therapeutics from May 2015 to August 2021 and Curis, Inc. from November 2016 to September 2022. Dr. Kunkel served as Chief Medical Officer of Pharmacyclics LLC from 2011 to 2013 and of Proteolix, Inc. from 2007 to 2009. Dr. Kunkel also serves as a scientific advisor to a number of public and private biotechnology companies. Dr. Kunkel received a B.A. in Biology from University of California, San Diego and an M.D. from the University of Southern California.
Lori A. Kunkel, M.D.
Board Director
Lori A. Kunkel, M.D.
Board Director
Lori A. Kunkel, M.D., has served as a member of our board of directors since July 2019. Dr. Kunkel is a biotechnology consultant at LAK505, LLC (previously D2D, LLC), where she advises on drug development, strategy and commercialization, a position she has held since 2004. Dr. Kunkel currently serves on the board of directors of Enliven Therapeutics, Inc., Oric Pharmaceuticals, Inc. and K36 Therapeutics, Inc. She previously served as a director of Loxo Oncology, Inc. from October 2014 until February 2019, Tocagen from September 2015 to June 2020, Maverick Therapeutics from May 2015 to August 2021 and Curis, Inc. from November 2016 to September 2022. Dr. Kunkel served as Chief Medical Officer of Pharmacyclics LLC from 2011 to 2013 and of Proteolix, Inc. from 2007 to 2009. Dr. Kunkel also serves as a scientific advisor to a number of public and private biotechnology companies. Dr. Kunkel received a B.A. in Biology from University of California, San Diego and an M.D. from the University of Southern California.
Lori A. Kunkel, M.D.
Board Director
David Lacey, M.D
Board Director
David Lacey, M.D., has served as a member of our board of directors since April 2016. He served as Chairman of our board of directors from August 2019 until May 2024. Dr. Lacey is a biopharmaceutical consultant at David L. Lacey LLC, where he advises academic institutions, biotechnology companies, and venture capital firms, a position he has held since July 2011. Dr. Lacey currently serves on the board of directors of Arcus Biosciences, Inc.and Inbiomotion SL. From 1994 until his retirement in 2011, Dr. Lacey held various positions, including Senior Vice President of Discovery Research, at Amgen Inc. Dr. Lacey holds a B.A. in Biology from the University of Colorado, Denver and an M.D. from the University of Colorado School of Medicine.
David Lacey, M.D
Board Director
David Lacey, M.D
Board Director
David Lacey, M.D., has served as a member of our board of directors since April 2016. He served as Chairman of our board of directors from August 2019 until May 2024. Dr. Lacey is a biopharmaceutical consultant at David L. Lacey LLC, where he advises academic institutions, biotechnology companies, and venture capital firms, a position he has held since July 2011. Dr. Lacey currently serves on the board of directors of Arcus Biosciences, Inc.and Inbiomotion SL. From 1994 until his retirement in 2011, Dr. Lacey held various positions, including Senior Vice President of Discovery Research, at Amgen Inc. Dr. Lacey holds a B.A. in Biology from the University of Colorado, Denver and an M.D. from the University of Colorado School of Medicine.
David Lacey, M.D
Board Director
Judith A. Reinsdorf, J.D.
Board Director
Judy Reinsdorf has served as a member of our board of directors since October 2021. Ms. Reinsdorf has extensive experience in executive roles across multiple industries. She most recently served as executive vice president and general counsel of Johnson Controls International, a global leader in building products and technology and integrated solutions, from September 2016 to November 2017, following its merger with Tyco International, where she served as executive vice president and general counsel from March 2007 until September 2016. She currently serves on the board of directors of Enpro Inc. and Toll Brothers, Inc., on the board of trustees of the University of Rochester, and on the board of the NACD New Jersey Chapter. Previously, Ms. Reinsdorf served on the boards of Alexion Pharmaceuticals, Inc. until its acquisition by Astra Zeneca in 2021, The Dun & Bradstreet Corporation from 2013 until 2019 and Cornerstone Building Brands, Inc. from 2021 until it was taken private in 2022. She began her career in 1989 as an associate at Crowell & Moring and held various legal counsel positions at Monsanto, Pharmacia and C.R. Bard. Ms. Reinsdorf holds a B.A. from the University of Rochester and a J.D. from Cornell Law School.
Judith A. Reinsdorf, J.D.
Board Director
Judith A. Reinsdorf, J.D.
Board Director
Judy Reinsdorf has served as a member of our board of directors since October 2021. Ms. Reinsdorf has extensive experience in executive roles across multiple industries. She most recently served as executive vice president and general counsel of Johnson Controls International, a global leader in building products and technology and integrated solutions, from September 2016 to November 2017, following its merger with Tyco International, where she served as executive vice president and general counsel from March 2007 until September 2016. She currently serves on the board of directors of Enpro Inc. and Toll Brothers, Inc., on the board of trustees of the University of Rochester, and on the board of the NACD New Jersey Chapter. Previously, Ms. Reinsdorf served on the boards of Alexion Pharmaceuticals, Inc. until its acquisition by Astra Zeneca in 2021, The Dun & Bradstreet Corporation from 2013 until 2019 and Cornerstone Building Brands, Inc. from 2021 until it was taken private in 2022. She began her career in 1989 as an associate at Crowell & Moring and held various legal counsel positions at Monsanto, Pharmacia and C.R. Bard. Ms. Reinsdorf holds a B.A. from the University of Rochester and a J.D. from Cornell Law School.
Judith A. Reinsdorf, J.D.
Board Director
Edward C. Saltzman
Board Director
Edward C. Saltzman has served as a member of our board of directors since September 2022. Mr. Saltzman has nearly four decades of consulting and strategic development experience in the pharmaceutical, specialty pharmaceutical and biotechnology industries. He currently serves as a Senior Strategic Advisor for Lumanity Inc., an Arsenal Capital Partners company focused on improving patient health by accelerating and optimizing access to medical advances, and served as Lumanity’s Head of Biotech Strategy from March 2022 until March 2023. In 1993, Mr. Saltzman founded Defined Health Inc., an asset development strategy consulting firm, and led it to becoming a preeminent advisor to senior management and boards of directors of biotechnology and biopharmaceutical companies, including those developing novel drug discovery platforms. Following the sale of Defined Health to Cello Health plc in January 2017, Mr. Saltzman served as President of Cello Health’s bio-consulting business unit until mid 2017, when he became the unit’s Executive Chairman, a position he held until March of 2022 when Cello Health was merged with several other businesses and renamed Lumanity. Mr. Saltzman is a frequent speaker on industry issues and is a past recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Mr. Saltzman currently is a Venture Advisor to the Israel Biotech Fund. Mr. Saltzman previously served on the board of directors of Vidac Pharmaceuticals Inc. and Saniona AB. Mr. Saltzman holds a bachelor’s degree in Journalism from New York University.
Edward C. Saltzman
Board Director
Edward C. Saltzman
Board Director
Edward C. Saltzman has served as a member of our board of directors since September 2022. Mr. Saltzman has nearly four decades of consulting and strategic development experience in the pharmaceutical, specialty pharmaceutical and biotechnology industries. He currently serves as a Senior Strategic Advisor for Lumanity Inc., an Arsenal Capital Partners company focused on improving patient health by accelerating and optimizing access to medical advances, and served as Lumanity’s Head of Biotech Strategy from March 2022 until March 2023. In 1993, Mr. Saltzman founded Defined Health Inc., an asset development strategy consulting firm, and led it to becoming a preeminent advisor to senior management and boards of directors of biotechnology and biopharmaceutical companies, including those developing novel drug discovery platforms. Following the sale of Defined Health to Cello Health plc in January 2017, Mr. Saltzman served as President of Cello Health’s bio-consulting business unit until mid 2017, when he became the unit’s Executive Chairman, a position he held until March of 2022 when Cello Health was merged with several other businesses and renamed Lumanity. Mr. Saltzman is a frequent speaker on industry issues and is a past recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Mr. Saltzman currently is a Venture Advisor to the Israel Biotech Fund. Mr. Saltzman previously served on the board of directors of Vidac Pharmaceuticals Inc. and Saniona AB. Mr. Saltzman holds a bachelor’s degree in Journalism from New York University.
Edward C. Saltzman
Board Director
Paul M. Silva
Board Director
Paul M. Silva has served as a member of our board of directors since October 2021. Mr. Silva is a biotechnology leader with more than 30 years of finance and operational experience. He served as senior vice president, chief accounting officer, at Vertex Pharmaceuticals Incorporated, a global biotechnology company, from April 2011 until his retirement in April 2021, and also served as the company’s interim chief financial officer from January 2019 to April 2019. Mr. Silva joined Vertex in August 2007 and was the company’s vice president and corporate controller from September 2008 through April 2011. Prior to Vertex, he held positions at Iron Mountain Incorporated, Thermo Electron Corporation, and Anderson LLP. Mr. Silva currently serves on the board of directors of Rapport Therapeutics, Inc. Mr. Silva holds a B.S. in accounting from Assumption College.
Paul M. Silva
Board Director
Paul M. Silva
Board Director
Paul M. Silva has served as a member of our board of directors since October 2021. Mr. Silva is a biotechnology leader with more than 30 years of finance and operational experience. He served as senior vice president, chief accounting officer, at Vertex Pharmaceuticals Incorporated, a global biotechnology company, from April 2011 until his retirement in April 2021, and also served as the company’s interim chief financial officer from January 2019 to April 2019. Mr. Silva joined Vertex in August 2007 and was the company’s vice president and corporate controller from September 2008 through April 2011. Prior to Vertex, he held positions at Iron Mountain Incorporated, Thermo Electron Corporation, and Anderson LLP. Mr. Silva currently serves on the board of directors of Rapport Therapeutics, Inc. Mr. Silva holds a B.S. in accounting from Assumption College.
Paul M. Silva
Board Director
Roy Baynes, MB.Bch., M.Med., Ph.D.
Clinical Advisor
Roy Baynes, MB.Bch., M.Med., Ph.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Baynes currently serves as Chief Medical Officer at Eikon Therapeutics, Inc. Dr. Baynes previously served as Chief Medical Officer at Merck & Co., where he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including pembrolizumab, a humanized monoclonal antibody used in cancer immunotherapy that treats some 17 different tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit as well as holding the Charles Martin endowed chair of Cancer Research at Wayne State University. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
Roy Baynes, MB.Bch., M.Med., Ph.D.
Clinical Advisor
Roy Baynes, MB.Bch., M.Med., Ph.D.
Clinical Advisor
Roy Baynes, MB.Bch., M.Med., Ph.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Baynes currently serves as Chief Medical Officer at Eikon Therapeutics, Inc. Dr. Baynes previously served as Chief Medical Officer at Merck & Co., where he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including pembrolizumab, a humanized monoclonal antibody used in cancer immunotherapy that treats some 17 different tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit as well as holding the Charles Martin endowed chair of Cancer Research at Wayne State University. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
Roy Baynes, MB.Bch., M.Med., Ph.D.
Clinical Advisor
John Kuriyan, Ph.D.
Scientific Advisor
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
John Kuriyan, Ph.D.
Scientific Advisor
John Kuriyan, Ph.D.
Scientific Advisor
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
John Kuriyan, Ph.D.
Scientific Advisor
Ronald Levy, M.D.
Clinical Advisor
Ronald Levy, M.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab, the first FDA-approved antibody for the treatment of lymphoma. Dr. Levy holds an A.B. in Biochemistry from Harvard University and an M.D. from Stanford University.
Ronald Levy, M.D.
Clinical Advisor
Ronald Levy, M.D.
Clinical Advisor
Ronald Levy, M.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab, the first FDA-approved antibody for the treatment of lymphoma. Dr. Levy holds an A.B. in Biochemistry from Harvard University and an M.D. from Stanford University.
Ronald Levy, M.D.
Clinical Advisor
Arthur Weiss, M.D., Ph.D.
Scientific Advisor
Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is Professor Emeritus, Medicine, at the University of California at San Francisco and a retired Howard Hughes Medical Institute Investigator. He previously served as Ephraim P. Engleman Distinguished Professor at UCSF and was the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Arthur Weiss, M.D., Ph.D.
Scientific Advisor
Arthur Weiss, M.D., Ph.D.
Scientific Advisor
Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is Professor Emeritus, Medicine, at the University of California at San Francisco and a retired Howard Hughes Medical Institute Investigator. He previously served as Ephraim P. Engleman Distinguished Professor at UCSF and was the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Arthur Weiss, M.D., Ph.D.
Scientific Advisor